GSK receives FDA approvable letter for Requip CF
WASHINGTON GlaxoSmithKline announced that the Food and Drug Administration has issued an approvable letter for the new drug application for Requip CR extended-release tablets, a treatment for moderate-to-severe primary restless legs syndrome.
This decision does not affect the current formulation of Requip (ropinirole hydrochloride) tablets, GSK said. An FDA approvable letter indicates that a drug may reach approval, but only after additional data are presented.
According to the company, Requip CR is an investigational extended-release formulation that is designed to provide a maximum of 14-hour coverage for those patients whose symptoms begin in the late afternoon or early evening hours. The company said it is committed to working with the FDA to address any questions or concerns the agency still has.